Invitrogen™ Blinatumomab Recombinant Mouse Monoclonal Antibody

Mouse Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541729

Catalog No. PIMA541729

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. Blinatumomab was approved in December 2014 under the FDA's accelerated approval program, which allows approval of a pharmaceutical to treat a serious or life-threatening disease based on clinical data showing the pharmaceutical has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.

Specifications

• Antigen: Blinatumomab
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: AMG103; BITE MT-103; bscCD19xCD3; MEDI-538; MT103
• Immunogen: Human CD19/CD3E.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA
• Concentration: 1.61 mg/mL
• Formulation: 30mM histidine with 10% sucrose, 0.02% Tween 80 and no preservative; pH 5.8
• Host Species: Mouse
• Purification Method: Metal-chelate chromatography
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: scFv κ

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov